In patients with colorectal and pancreatic cancer, LRG1 levels tends to be positively correlated with more advanced cancer stages and worse prognosis, and the PPARβ/δ agonist, GW501516, significantly increases LRG1 expression, strongly indicating that LRG1 is a direct target of PPARβ/δ (Zhou et al., 2017; Liu et al., 2019b; Xie et al., 2019). Here, LRG1 is linked to cancer.